Transcode Therapeutics, INC DEF 14A proxy statements

TransCode Therapeutics, Inc. completes the acquisition of immuno-oncology firm ABCJ, LLC, adding a phase 3-ready melanoma vaccine to its pipeline, alongside a $25 million investment.

TransCode Therapeutics amended its Series A and B Preferred Stock terms, clarifying conversion limits and removing delisting-triggered conversion rights, pending shareholder approval for a larger transaction.

TransCode Therapeutics, Inc. filed an amendment to its Form 8-K/A, clarifying the effective date and rights agent for its Contingent Value Rights Agreement, which outlines future payments to shareholders from asset monetization.

TransCode Therapeutics, Inc. filed an amendment to correct the price per share for its Series B Preferred Stock, detailing the acquisition of ABCJ, LLC and a concurrent $25 million private placement investment from DEFJ, LLC.

TransCode Therapeutics announced the acquisition of Polynoma LLC and a concurrent $25 million strategic financing from a CK Life Sciences subsidiary, expanding its oncology pipeline with a Phase 3-ready asset.

TransCode Therapeutics, Inc. announced its 2025 Annual Meeting of Stockholders will be held virtually on August 29, 2025, to vote on the election of four directors, an amendment to increase shares available under its 2021 Stock Option and Incentive Plan by 166,724 shares, and the ratification of its independent registered public accounting firm.

TransCode Therapeutics adjourns its Special Meeting to May 2, 2025, to gather more votes for a proposed reverse stock split.

TransCode Therapeutics is asking shareholders to vote in favor of a reverse stock split at a special meeting on April 21st to maintain its NASDAQ listing and facilitate future capital raising.

TransCode Therapeutics is asking stockholders to approve a reverse stock split to maintain its Nasdaq listing and potentially attract a broader range of investors.

TransCode Therapeutics has adjourned its Special Meeting to February 25, 2025, to gather more votes for proposals related to warrant adjustments and share issuance.

TransCode Therapeutics is holding a special meeting to seek stockholder approval for the issuance of shares upon exercise of warrants and to potentially adjourn the meeting if necessary to solicit additional votes.

TransCode Therapeutics is asking shareholders to authorize a reverse stock split to maintain its Nasdaq listing, which is crucial for raising capital and avoiding delisting.

TransCode Therapeutics has been granted an extension by Nasdaq to regain compliance with listing requirements, subject to certain conditions.

TransCode Therapeutics is holding a special meeting to seek stockholder approval for ratifying a prior securities offering and implementing a reverse stock split to address Nasdaq listing deficiencies.

TransCode Therapeutics has regained compliance with Nasdaq listing standards, ensuring its stock will remain listed on the exchange.

TransCode Therapeutics files an amendment to its proxy statement to correct the description of the quorum requirement for its upcoming Annual Meeting of Stockholders.

TransCode Therapeutics is asking stockholders to approve a reverse stock split and an amendment to its stock option and incentive plan at the upcoming annual meeting.

TransCode Therapeutics is seeking shareholder authorization for a reverse stock split to maintain its Nasdaq listing after failing to meet the minimum bid requirement.

TransCode Therapeutics is holding its 2024 Annual Meeting of Stockholders on June 13, 2024, to elect directors, approve an amendment to the 2021 Stock Option and Incentive Plan, and ratify the appointment of its independent registered public accounting firm.